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All isolates of serotype M1 of group A streptococci possess a gene for streptococcal inhibitor of complement (SIC)
in the mga regulon, which harbors genes for other virulence factors, such as M and M-like proteins, C5a peptidase,
and a regulator. In serotype M57 the gene for a protein that is closely related to SIC (crs57) is located outside the
mga regulon. We mapped the location of the crs57 gene in six strains of emm57 (gene encoding the M57 protein)
sequence types to an intergenic region between the ABC transporter gene (SPy0778) and the gene for a small
ribosomal protein (rpsU). The noncoding sequences on both sides of crs57 exhibited high degrees of identity to the
corresponding regions of sic from M1 strains. This included one of the inverted repeat sequences of IS1562 but not
the insertion element itself. These observations suggest that crs57 was recently acquired by serotype M57 or its
progenitor via horizontal acquisition from serotype M1. The six emm57 sequence type isolates analyzed in this study
belong to two distinct molecular types (vir types VT8 and VT101). Although the crs57 sequences from VT8 strains
had very few substitution mutations, the VT101 crs57 sequence had a large number of such mutations. The CRS57
proteins from these strains are secretory products and have the ability to bind to complement proteins. All these
proteins contain several tryptophan-rich repeats designated DWS motifs and internal repeat sequences. In all of
these structural and biochemical characteristics CRS57 resembles SIC from M1 strains. Hence, CRS57 has a
functional role similar to that of SIC in an M1 strain.
Group A streptococcus (GAS) (Streptococcus pyogenes) is a
human-specific pathogen that is responsible for a wide range of
diseases, including immune-mediated postinfective sequelae,
such as acute rheumatic fever and post-streptococcus glomer-
ulonephritis. This pathogen has evolved diverse mechanisms to
overcome host defenses against infection. The surface-exposed
major protective antigen, M protein, binds to factor H and
thereby may inhibit deposition of opsonin C3b on the GAS
surface (9). M protein also binds to a 570-kDa human plasma
protein designated C4b-binding protein that inhibits comple-
ment activation via the classical pathway (3, 15). All S. pyogenes
strains express a specific protease that cleaves chemotactic
complement C5a protein (4) to an inactive molecule, retarding
phagocyte recruitment at the site of infection. Additionally,
isolates of S. pyogenes with M1-type specificity express a secre-
tory protein designated SIC (streptococcal inhibitor of com-
plement function) that inhibits complement-mediated cell lysis
(1). While the biological significance of SIC as an inhibitor of
complement function is not clear, the presence of the gene
encoding it in all serotype M1 strains (1), the extreme diver-
gence (20), and the rapid emergence of variants (14) indicate
that this protein has an important biological role. In fact,
recent studies of SIC showed that it also inhibits the functions
of innate immune proteins, such as secretory leukocyte pro-
teinase inhibitor and lysozyme (5).
Biochemical studies have suggested that SIC interferes with
the function of the membrane attack complex by possibly bind-
ing to one or more protein components associated with the
complex (1). Fernie-King et al. (6) showed that M1 SIC binds
to the C6 and C7 complement proteins, preventing their in-
corporation into the membrane attack complex. Despite con-
siderable sequence diversity, all SIC variants from M1 strains
have the complement-inhibiting activity (14).
Molecular studies (12) have shown that like serotype M1
strains, all serotype M57 strains possess a gene which encodes
a protein closely related to the M1 SIC, designated CRS
(closely related to SIC). However, while the gene encoding SIC
is part of the M1 mga regulon, which comprises genes encoding
M or M-like proteins (emm or emmL), C5a peptidase (scpA),
and a regulator (mga), the crs57 gene (the gene encoding
CRS57 in M57 strains) is located outside the mga regulon in
M57 strains. While most studies have been carried out with
SIC variants of M1 strains, little is known about CRS57. In this
study, we determined the exact location of crs57 in the M57
genome, examined the diversity of CRS57 from six M57 iso-
lates belonging two distinct molecular types (vir types), and
tested the ability of the molecules to bind to the complement
proteins. CRS57 is highly conserved in the major vir type
(VT8) of M57 strains, whereas in the minor vir type (VT101)
the protein is more diverse than VT8 CRS57. We show here
that the CRS57 proteins are excretory products and that they
have the ability to bind to the C6 and C7 complement proteins.
Taken together, our results are consistent with single lateral
acquisition of the sic gene from an emm1 strain by M57 or its
progenitor.
MATERIALS AND METHODS
Strains, culture, and genomic DNA. Table 1 summarizes information about the
S. pyogenes strains used in this study. S. pyogenes serotype M1 and 57 reference
strains (strains 2031 and 2077, respectively) were obtained from Public Health
Laboratory Services, Prague, Czech Republic. All other strains were isolates ob-
* Corresponding author. Mailing address: Queensland Institute of
Medical Research, 300 Herston Road, Herston, Qld 4006, Australia.












tained in the Northern Territory (NT). The GAS isolates were typed by vir typing
(Fig. 1). Vir typing is based on restriction fragment length polymorphism of the mga
regulon (8, 11, 12). Growth of GAS and genomic DNA extraction were carried out
as described previously (10).
Sequencing of crs57. Based on a partial sequence for crs57 (accession numbers
AF060764 and AF060765) (12), a specific reverse primer (primer crs57R; GAG
ACAAACCAACTCCAGACCGG) corresponding to this gene was designed. To
determine the sequence upstream of crs57, a bubble PCR was employed (17).
Genomic DNA was digested with Sau3A1, and to 15 g of the digest, 10 g of
preannealed linker oligonucleotides (GCACGTCTGACGATCTCAGTACAG
ACTGGAGTCACAGCTGC and GATCGCAGCTGTGACTTAGTCACTCC
AATGATCTGTCAGACGTGC) containing a Sau3A1 overhang and an internal
mismatch (bubble) was ligated. Three units of T4 DNA ligase in 10 buffer
containing ATP (Amersham) was used. The ligation product was then used as a
template in a PCR with Taq DNA polymerase (Amersham) by using the bubble-
specific primer (GACGATCTCAGTACAGACTG) and the crs57R primer. The
cycling conditions were 95°C for 30 s for denaturation, 53°C for 30s for annealing,
and 68°C for 90 s for extension. The bubble PCR amplified a product corre-
sponding to a region between the crs57R target site and an upstream Sau3A1
site. Sequencing of the PCR product from an emm57 strain revealed 112 bp
which exhibited 96% homology to the 3 end of an ABC transporter (Spy0778)
immediately adjoining a gene encoding a small ribosomal protein subunit (rpsU)
(data not shown). Based on these results and the S. pyogenes genomic sequence
data (accession number AE004092), we designed primers ABCF2 and rpsUR1
(GATCTGGCTTTAGCACCCTTTAGC and GATCTGGCTTTAGCACCCTT
TAGC´, respectively) spanning the region between Spy0778 and rpsU. A PCR
product that was about 2 kb long was obtained from all six emm57 strains, while
PCR with M1 and sic-negative strains resulted in a product that was approxi-
mately 400 bp long (Fig. 2). The complete sequence of the PCR product from the
emm57 strains was determined.
Production of recombinant CRS57. The CRS57 gene was amplified by using
oligonucleotides CTACTAGGAGCTACACAACC and CGTTGCTGATGGT
GTATATGG. Recombinant CRS57 constructs were then generated in either the
pQE30 expression system (Qiagen) or the pBAD/TOPO TA (Thiofusion) ex-
pression system (Invitrogen). Sticky-end cloning of sic into pQE30 was per-
formed at the BamHI and PstI (New England Biolabs) restriction enzymes sites.
DNA manipulation, transformation, expression, and purification were per-
formed according to the manufacturer’s recommendations. The pBAD TA con-
structs in TOP10 cells (Invitrogen) were screened by PCR. Sequence analysis (by
using an ABI 3700 DNA sequencer and the BigDye 3 terminator mixture) was
performed to confirm positive clones. Plasmid preparations of positive clones
were transformed in Escherichia coli BL21 for expression. One-liter cultures of
BL21 containing the recombinant plasmid were grown in Luria-Bertani broth
with 100 g of ampicillin per ml until the optical density at 600 nm reached 0.5.
The best yields with the pBAD system were obtained upon induction with 0.2%
arabinose for 2 h.
To purify recombinant His-tagged CRS57, cell pellets from induced cultures
were sonicated to lyse the cells and centrifuged to remove the insoluble cellular
debris. The expressed recombinant protein was isolated from the resultant
cleared lysate by using a Superflow Ni-nitrilotriacetic acid column (Qiagen) and
the Biologic HR system (fast protein liquid chromatography; Bio-Rad). The
recombinant SIC was eluted with an imidazole (ICN Biomedical) gradient (20 to
300 mM) and dialyzed against phosphate-buffered saline (PBS). Fractionation by
polyacrylamide gel electrophoresis (PAGE) (Gradipore; Miniprotean II; Bio-
Rad) followed by immunoblotting with anti-SIC (this study) and anti-His (In-
vitrogen) antibodies was used to identify the purified proteins.
Antibodies. CRS-specific rabbit antiserum (IMVS, Gilles Plains, South Aus-
tralia, Australia) was obtained by immunizing rabbits with recombinant M1 SIC
(pQE30; Qiagen) from reference strain 2031.
Detection of crs57 in culture supernatants. Overnight cultures (10 ml) of S.
pyogenes 2077, NS38, BSA16, BSA5, NS844, and NS27 in Todd-Hewitt broth
(Oxoid) were centrifuged at 12,000  g for 10 min, and 1 ml of each culture
supernatant was transferred to a new tube. The culture supernatants were con-
centrated by using trichloroacetic acid (final concentration, 10%) at 20°C for
approximately 20 min to induce precipitation. To retrieve the precipitated pro-
teins, each mixture was centrifuged at 16,000  g for 20 min. The supernatant
was discarded, and the pellet was resuspended in 100 l of 0.1 M NaOH. SIC was
detected by separation of the sample by PAGE (Gradipore; Miniprotean II;
Bio-Rad), followed by Western blotting and detection with anti-SIC antibody.
Binding of CRS57 to complement. Assays for binding of CRS57 to the comple-
ment proteins C6 and C7 were performed by using an enzyme-linked immunosor-
bent assay. Ninety-six-well plates (TITERTEK) were coated with recombinant pro-
teins (50 g/ml; CRS57 or control proteins) in PBS at 4°C overnight. After blocking
FIG. 1. Vir typing of emm57 strains was performed as described
previously (11). The amplified products of the mga regulon were di-
gested with HaeIII (A) or HinfI (B). A marker (1-kb ladder; New
England Biolabs) and strain 2031 (an M1 strain) were included (lanes
M and 7, respectively). Lanes 1 to 6, isolates 2077 (a reference strain
from Prague), NS1140, BSA16, BSA5, NS38, and NS48, respectively.






2077 VT8 emm57 Prague Present
NS1140 VT101 emm57 NT Present
NS38 VT8 emm57 NT Present
NS48 VT8 emm57 NT Present
BSA16 VT8 emm57 NT Present
BSA5 VT8 emm57 NT Present
2031 emm1 Prague Present
NS844 emm1 NT Present
NS27 NDb NT Absent
a The presence of the sic gene was determined by PCR by using CRS-specific
primers (12).
b ND, not determined.











with 5% skim milk in PBS, complement from human sera (diluted 1/100 in PBS) or
commercial C6 and C7 (diluted 1/1,000 in PBS; Sigma) were added and incubated
for 1 h at 37°C in a 100-l (final volume) mixture. The wells were then washed three
times with PBS containing 0.5% Tween. Horseradish peroxidase-conjugated second-
ary antibodies to the complement components C6 and C7 (diluted 1:1,000; ICN
Biomedical) were used to determine the extent of binding. The reaction mixture was
developed with 4-chloro-1-naphthol (Sigma), and the absorbance at 450 nm was
determined with a Bio-Rad benchmark microplate reader.
Nucleotide sequence accession numbers. Nucleotide sequences of the PCR
products obtained from the six independent isolates of the emm57 type have
been deposited in the GenBank database under accession numbers AY229856,
AY229857, AY229858, AY229859, AY229860, and AF060764.
RESULTS
Divergence of crs57 sequence. PCR performed with primers
flanking the 3 end of the ABC transporter gene (SPy0778) and
the 5 end of rpsU suggested that in all emm57 isolates the two
genes are farther apart than they are in serotype M1 strains or
39 other strains tested. Data for the six isolates of the emm57
sequence type and strains of representative non-emm57 se-
quence types are shown in Fig. 2. The six isolates of the emm57
sequence type belong to two distinct vir types, VT8 and VT101.
The results of a comparison of the SPy0778-rpsU regions in
emm1 and emm57 strains are presented schematically in Fig. 3.
In all six emm57 isolates tested, the region between the
SPy0778 and rpsU genes contained crs57. Remnants of the
emm1 mga regulon were present immediately upstream and
downstream of the crs57 gene. In emm1, there is an IS1562
sequence in reverse orientation between the sic gene and the
scpA gene. The IS1562 sequence was not found within the
SPy0778-rpsU region in the emm57 strains. However, the in-
tervening sequence between the sic gene and the IS1562 in M1,
including a copy of the terminal inverted repeat of the inser-
tion element, was conserved in the SPy0778-rpsU region in all
of the emm57 strains and occurred in the same position in
relation to the crs57 gene (Fig. 3). These findings suggest that
a crs57 gene was recently acquired by M57 or its progenitor,
possibly by horizontal transfer from M1.
The emm57 strains used in this study include one strain from
Prague (a reference strain) and five strains from the NT that
belong to two distinct vir types (Fig. 1). Interestingly, the vir
type profile of strain 2077 is identical to the VT8 profile. The
derived CRS57 sequences of all of the VT8 isolates are highly
homologous except for a few insertions or deletions of residues
(including short and long repeats) (Fig. 4). A comparison of
the corresponding DNA sequences also showed that there is a
silent mutation in addition to the mutations that account for
the amino acid changes. By contrast, the crs57 gene in NS1140,
which is a VT101 strain, had several replacement mutations.
Interestingly however, examination of the C-proximal half of
the NS1140 CRS57 revealed a greater resemblance to the
corresponding region of SIC from strain AP1 than to the cor-
responding region of VT8 CRS57. A comparison of the sic
FIG. 2. PCR amplification of the SPy0778-rpsU intergenic region in
isolates of the emm57 sequence type (lanes 1 to 6), in an isolate of the
emm1 sequence type (lane 7), and in NS27 (lane 8). Lanes 1 to 6,
amplification products from 2077, NS1140, BSA16, BSA5, NS38, and
NS48, respectively. Lane M contained HindIII-digested lambda phage
DNA as a size marker.
FIG. 3. Comparison of part of the mga locus in M1 and the SPy0778-rpsU region in M57 and other strains. The shaded areas in the SPy0778-rpsU
region represent homologous regions. The mottled area between the regions surrounding the sic gene in M1 and the regions surrounding the crs57 gene
in M57 shows a high level of similarity. This area also includes one of the inverted repeats of IS1562. The downward arrowheads beneath the mottled
rectangle suggest that there was horizontal acquisition of this region from M1. The horizontal arrows show the relative positions of the ABC-F2 and
rpsU-R1 primers used to amplify SPy0778-rpsU regions (the sequences are given in the text). The figure is not to scale.











sequence from strain AP1 (accession number X92968) and the
VT8 crs57 sequence showed that there was a relatively high
number of replacement mutations in the C-proximal third of
the molecule (26 replacements in the C-proximal third and 12
replacements in the rest of the protein). Of particular interest
is the conservation of tryptophan-containing short repeats. The
frequencies of the five amino acids surrounding the tryptophan
residues were determined (Fig. 5). The most conserved amino
acid residues in the first three of the five positions are (D/G)-
W-(S/G). We therefore refer to this as the DWS motif. The
M57 isolates tested in this study each had 15 to 21 DWS motifs.
CRS57 is an excretory product. The results described above
showed that the crs57 gene is at the end of the ABC trans-
porter immediately upstream of the rpsU gene in all of the
emm57 strains. Since all of the crs57 sequences analyzed have
a signal sequence, it is reasonable to expect that, like the SIC
protein, the CRS57 protein in these strains is an excretory
product. We confirmed this by analyzing culture supernatants
and whole-cell extracts from overnight cultures of all six
emm57 isolates by PAGE and Western blotting (Fig. 6; data
for NS1140 not shown). Anti-SIC antibodies reacted with 40-
to 50-kDa bands in culture supernatants of strain 2031 (a
positive control strain) and the emm57 strains, as reported
previously (6). The observed size differences between the
CRS57 proteins of different strains in Fig. 6 is consistent with
derived crs57 sequence data.
Demonstration of binding of CRS57 to complement proteins
C6 and C7. Binding of SIC from an M1 strain to intermediate
terminal complement complexes was recently demonstrated by
Fernie-King et al. (6). To show that recombinant CRS57 pro-
teins bind to C6 and C7 complement proteins in serum, we
purified the fusion protein containing thioredoxin (pBAD thio
cloning system). In our hands the expression of CRS57 in the
pQE system gave low yields, the recombinant proteins accu-
mulated in inclusion bodies, and the proteins were insoluble
and often degraded upon purification. The thioredoxin fusion
FIG. 4. Alignment of CRS57 from strains 2077, NS48, BSA5, NS38, BSA16, and NS1140 with SIC from M1 strain AP1. The three backgrounds
indicate levels of conservation. The residues conserved in all seven sequences are indicated by a black background, and the residues conserved in
five or six of the seven sequences are indicated by a grey background. The downward arrowheads indicate tryptophan residues conserved in at least
four sequences. The horizontal arrows indicate repeat sequences.











improved the yield, solubility, and stability of the recombinant
proteins considerably. Thioredoxin by itself did not bind to the
complement proteins (Fig. 7). Plates coated with the recombi-
nant proteins were reacted with human serum, and binding of
the C6 and C7 complement proteins was detected by using
secondary antibodies. The results demonstrated that the com-
plement component C6 and C7 proteins were bound to CRS57
(Fig. 7A). To confirm this, we also tested binding using purified
C6 and C7. In these experiments the recombinant CRS57
coated onto plates was reacted with the C6 and C7 proteins
(Fig. 7B). The results confirmed that there is an interaction
between the complement proteins and CRS57.
DISCUSSION
We reported previously (12) that in type 57 isolates the gene
for CRS57 is outside the mga regulon, which contains emm,
emm-like, scpA, and mga genes. In addition to confirming this,
in this study we showed that in all six type 57 isolates tested the
gene is located between the ABC transporter (SPy0778) and
the rpsU gene. The organization of the Spy0778-rpsU region is
highly conserved in the non-emm57 GAS strains tested and in
three genomic sequences (M1, M3, and M18) (2, 7, 18). The
CRS57 sequence of NS1140 exhibited considerable diversity
compared to the other CRS57 sequences analyzed. Despite the
difference, the junction points on either side of crs57 in all six
emm57 strains are highly conserved. These observations sug-
gest that horizontal acquisition of the crs gene must have been
a one-off process and may have been a recent evolutionary
event. Recently, Ma et al. (16) found that sic was distributed in
a greater number of strains when they examined pharyngitis
isolates from Japanese children. We believe that if horizontal
acquisition was the mode of spread of sic among GAS strains,
as these authors indicate, the source may been serotype M1
because this serotype has an intact IS1562.
Since CRS57 proteins have all of the structural characteris-
tics of the SIC from an M1 strain, it is reasonable to expect that
FIG. 5. Frequency of residues within the tryptophan-containing
short repeat domains. To generate the frequency histogram, the BSA5-
derived amino acid sequence data were used. There were 21 trypto-
phan residues, 19 of which were in the short conserved motifs. The
letters within the bars indicate the amino acid residues. The sections of
the bars labeled “others” could include up to four different residues.
FIG. 6. Expression of CRS57 by M57 strains. Supernatants of over-
night cultures of GAS strains were concentrated by precipitation in
10% cold trichloroacetic acid for 1 h. Each pellet was dissolved in 100
mM NaOH. The samples (40 l) were electrophoresed in 4 to 12%
(Gradipore) acrylamide under denaturing conditions. (A) Ponceau-
stained membrane. (B) Western blot of the same gel reacted with
polyclonal rabbit serum raised against SIC from M1 strain 2031. Lane
M contained a marker. Lane 1, recombinant SIC from M1; lanes 2 to
7, culture supernatants from 2077, NS38, BAS16, BSA5, NS844 (an NT
emm1 strain), and NS27 (a SIC-negative strain), respectively.
FIG. 7. Binding of CRS57 to the complement C6 (solid bars) and
C7 (open bars) proteins as determined by an enzyme-linked immu-
nosorbent assay. (A) Binding to the complement proteins in the sera.
(B) Binding to the purified C6 and C7 components. CRS1 and CRS57
were recombinant CRS proteins from strains 2031 and BSA5, respec-
tively. The controls included recombinant His-tagged thioredoxin
(thio), bovine serum albumin (BSA), and PBS (no coat). The data are
averages for triplicate experiments for each protein, and the error bars
indicate standard deviations. OD540, optical density at 540 nm.











CRS57 proteins also have similar biological properties. We
tested this hypothesis by determining whether the CRS57 pro-
teins, like SIC from M1 strains, bind to the C6 and C7 com-
plement proteins. Our results show that the CRS57 proteins
interact with the complement proteins. Hence, it may be in-
ferred that CRS57 has the same properties as SIC from M1
with respect to the interaction with the complement proteins.
Recent serological observations in the NT indigenous pop-
ulation, in which post-streptococcus glomerulonephritis is
highly endemic, revealed that 57% of the population has an-
tibodies to SIC (19). However, isolation of type 1 or close
relatives of this type from this population has been rare in the
last 10 years (unpublished observations). By contrast, the rate
of isolation of emm57 strains is high. Thus, at least the newly
acquired antibodies to SIC in our study population are most
likely due to emm57 strains. If so, this further supports our
hypothesis that CRS57 is expressed and is antigenic during
natural infection. Thus, if antibodies confer selection pressure
for variants of sic from M1 strains (as proposed by Hoe et al.
[14]), the same pressure could also operate to select variants of
crs57 given that SIC and CRS57 have common biological and
biochemical properties. Whereas a large number of mutations
have been observed in the crs57 gene from VT101, the fre-
quency of point mutations in the remaining five epidemiolog-
ically unrelated emm57 isolates was low; only short insertions
or deletions, particularly of the repeat sequences, accounted
for most of the mutations.
The mga regulon harbors antigenically highly variable genes.
This regulon may be a mutational hot spot in the GAS genome.
Since in M57 the crs57 gene is outside this region, it may be less
prone to mutations than sic from M1.
All CRS proteins have short conserved DWS repeats. The
tryptophan content of some CRS molecules could be as high as
6%. The role of the conserved tryptophan-containing motif is
not known. In some proteins tryptophan-rich motifs may have
a role in membrane binding. For instance, streptolysin O, a
thiol-activated cytolysin, has a tryptophan-rich domain in the
C-terminal region which is essential for membrane binding
(21). Since SIC is known to enter host cells efficiently (13), it is
possible that the DWS motif is responsible for promoting an
interaction between SIC and the host cell membrane. Further
work to test this hypothesis is in progress.
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